Abstract
The antipsychotic treatment in pregnancy presents difficult clinical decision based on a careful risk-benefit ratio for a woman and for a fetus. The main risk for the woman is the worsening of psychosis; the fetus is in risk of congenital developmental abnormalities.
If it is possible we prefer the non-pharmacological treatment. But in the most cases we have to choose the pharmacological treatment, continuous antipsychotic monotherapy is preferred using the minimum effective dose.
The use of high-potency antipsychotics is preferable for the treatment, for atypical antipsychotics we have only a fes data about the effect on the fetus. Sulporide is the only exception, the clinical trails with sulpiride seems to be relatively safe.
Women taking antipsychotics would not breast feed.